MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. AMC
5. FFAI
6. PAA
7. TLT
8. NVDA
9. NUAI
10. MSFT

Go back to MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
(NASDAQ: INKT) Delayed: 12.05 --0 (-0%)
Previous Close $12.05    52 Week High $ 
Open $12.05    52 Week Low $ 
Day High $12.05    P/E N/A 
Day Low $12.05    EPS $ 
Volume 304